Haemonetics FY2025 EPS Estimate Reduced by Zacks Research

Haemonetics Co. (NYSE:HAE) – Equities researchers at Zacks Research cut their FY2025 earnings per share (EPS) estimates for shares of Haemonetics in a report released on Thursday, March 13th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings of $4.54 per share for the year, down from their previous forecast of $4.56. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2025 earnings at $1.21 EPS, Q1 2026 earnings at $1.11 EPS, Q2 2026 earnings at $1.22 EPS, Q3 2026 earnings at $1.34 EPS, Q4 2026 earnings at $1.34 EPS, FY2026 earnings at $5.00 EPS, Q1 2027 earnings at $1.37 EPS and FY2027 earnings at $5.73 EPS.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%.

Several other research analysts also recently issued reports on the company. Raymond James restated a “strong-buy” rating and set a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and cut their price target for the company from $95.00 to $68.00 in a report on Friday, February 7th. Barrington Research cut their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a report on Friday, February 7th. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Finally, Needham & Company LLC cut their price target on Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Haemonetics presently has a consensus rating of “Moderate Buy” and a consensus target price of $101.22.

Haemonetics Trading Down 0.2 %

Shares of Haemonetics stock opened at $64.69 on Monday. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. Haemonetics has a 1 year low of $58.80 and a 1 year high of $97.97. The company has a market capitalization of $3.25 billion, a P/E ratio of 25.47, a P/E/G ratio of 1.11 and a beta of 0.43. The business has a 50 day moving average price of $68.08 and a 200 day moving average price of $75.26.

Institutional Trading of Haemonetics

Institutional investors and hedge funds have recently made changes to their positions in the company. TD Waterhouse Canada Inc. acquired a new stake in shares of Haemonetics during the 4th quarter worth $25,000. Covestor Ltd increased its holdings in shares of Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 439 shares during the last quarter. Whittier Trust Co. purchased a new stake in Haemonetics during the 4th quarter worth $62,000. Parkside Financial Bank & Trust boosted its position in Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 240 shares during the period. Finally, AlphaQuest LLC boosted its position in Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after purchasing an additional 1,826 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.